Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 08-24-2018, 06:21 PM #1
eds195 eds195 is offline
Member
 
Join Date: Feb 2015
Location: NJ
Posts: 153
8 yr Member
eds195 eds195 is offline
Member
 
Join Date: Feb 2015
Location: NJ
Posts: 153
8 yr Member
Default Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s

Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s

Phase 2 Trial Shows Nilotinib Potential to Modulate Dopamine in Parkinson’s
eds195 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Betsy859 (10-18-2018), jeffreyn (08-25-2018), RooJr (08-25-2018)

advertisement
Old 08-25-2018, 02:57 AM #2
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
johnt johnt is offline
Senior Member
 
Join Date: Apr 2009
Location: Stafford, UK
Posts: 1,059
10 yr Member
Default

I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf

The conclusions:

"a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."

John
__________________
Born 1955. Diagnosed PD 2005.
Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg
Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg
johnt is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
RooJr (08-25-2018)
Old 08-25-2018, 04:06 AM #3
RooJr RooJr is offline
Junior Member
 
Join Date: Sep 2015
Posts: 32
8 yr Member
RooJr RooJr is offline
Junior Member
 
Join Date: Sep 2015
Posts: 32
8 yr Member
Default

Quote:
Originally Posted by johnt View Post
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf

The conclusions:

"a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."

John
Great Find!
RooJr is offline   Reply With QuoteReply With Quote
Old 08-25-2018, 06:49 AM #4
jeffreyn jeffreyn is offline
Member
 
Join Date: Apr 2016
Location: Australia
Posts: 352
5 yr Member
jeffreyn jeffreyn is offline
Member
 
Join Date: Apr 2016
Location: Australia
Posts: 352
5 yr Member
Default Too soon

I think an "abstract" is all we are likely to get for quite a while yet. As it says in the PNT article, the Georgetown Phase 2 trial is still ongoing.
jeffreyn is offline   Reply With QuoteReply With Quote
Old 08-25-2018, 08:49 PM #5
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
Default

Quote:
Originally Posted by jeffreyn View Post
I think an "abstract" is all we are likely to get for quite a while yet. As it says in the PNT article, the Georgetown Phase 2 trial is still ongoing.
If the present trials show continued safety and success will this drug get fast track status as a breakthrough therapy? Indications so far sure suggest that it qualifies!

https://www.fda.gov/forpatients/appr...st/default.htm
zanpar321 is offline   Reply With QuoteReply With Quote
Old 08-26-2018, 02:15 AM #6
jeffreyn jeffreyn is offline
Member
 
Join Date: Apr 2016
Location: Australia
Posts: 352
5 yr Member
jeffreyn jeffreyn is offline
Member
 
Join Date: Apr 2016
Location: Australia
Posts: 352
5 yr Member
Default

From the conclusion:
"Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."

I had a lot of trouble understanding this sentence, and I found the PNT article to be of no help in that regard.

Assuming I've understood it correctly, here is an alternative wording that might (or might not!) be clearer:
"The dose-dependent decrease in oligomeric alpha-synuclein levels (and increase in HVA/DOPAC levels) suggests that (to potentially halt PD progression) the stage-of-disease may dictate the appropriate dose of nilotinib to administer."

Anyway, it seems to me that there is still a lot of research to be done to establish the correct dose for each stage of the disease. This might well affect the prospects for a fast-track approval.

Hopefully, another write-up will appear (from AlzForum, SoPD blog, ...) and shed some more light.
jeffreyn is offline   Reply With QuoteReply With Quote
Old 08-27-2018, 04:31 PM #7
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
zanpar321 zanpar321 is offline
Member
 
Join Date: Feb 2014
Posts: 365
10 yr Member
Default

Quote:
Originally Posted by jeffreyn View Post
From the conclusion:
"Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."

I had a lot of trouble understanding this sentence, and I found the PNT article to be of no help in that regard.

Assuming I've understood it correctly, here is an alternative wording that might (or might not!) be clearer:
"The dose-dependent decrease in oligomeric alpha-synuclein levels (and increase in HVA/DOPAC levels) suggests that (to potentially halt PD progression) the stage-of-disease may dictate the appropriate dose of nilotinib to administer."

Anyway, it seems to me that there is still a lot of research to be done to establish the correct dose for each stage of the disease. This might well affect the prospects for a fast-track approval.

Hopefully, another write-up will appear (from AlzForum, SoPD blog, ...) and shed some more light.
Is Radotinib ABL to beat Nilotinib? | The Science of Parkinson's

June 17, 2018 - The competition to stop/reverse Parkinson's is intense!

Our efforts to slow/halt the progression of Parkinson’s are attempting to attack the condition on many different fronts, and (as in the case of the cAbl-inhibitors and GLP-1 agonists – see previous post) we now have multiple weapons potentially available on some of those battle lines.

Ironically in another recent post I commented about the crazy pace of the research at the moment (Click here for that post), and this post is a perfect example of that manic speed. Just days after publishing fascinating results dealing with a novel GLP-1 agonist in models of Parkinson’s, that same research group – led by Prof Han Seok Ko of Johns Hopkins University Medical school – published the research report that was reviewed in this post dealing with a completely different type of drug that exhibits interesting properties in models of Parkinson’s.

A lot of excitement is associated with the efforts to re-purpose the cancer drug Nilotinib for Parkinson’s, and today’s post reinforces the idea that other pharmaceutical companies are also focusing on shifting similar ABL inhibitor drugs to neurodegenerative conditions.

It will be interesting to see how quickly Ilyang Pharmaceutical initiates clinical testing of Radotinib for Parkinson’s.
zanpar321 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
Betsy859 (10-18-2018), eds195 (08-28-2018), KNPV (08-28-2018)
Old 09-16-2018, 07:15 PM #8
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default

Quote:
Originally Posted by johnt View Post
I can only find the Abstract describing this research:
https://www.iaprd-world-congress.com..._Abstracts.pdf

The conclusions:

"a single time oral administration of Nilotinib may increase brain dopamine levels and metabolism. These results suggest Nilotinib, in a dose dependent manner, may have a symptomatic effect through modulation of brain dopamine levels. Additionally, the significant reduction of oligomeric alpha-synuclein, which is expected to increase in the CSF of PD patients as the disease progresses, suggests that Nilotinib may reduce misfolded alpha-synuclein accumulation and have a longterm disease modifying effect. Importantly, the dose response of oligomeric alpha-synuclein and HVA changes to nilotinib suggests that the dose administered may depend on the stage of disease to potentially halt PD progression."

John

Yes, as Jeff replied, this was only presented as an Abstract at the Oral Poster Presentation of the 2018 iaprd. This is a common occurrence to present abstracts and posters of ongoing clinical resesrch to provide updates as data is analysed.
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
anagirl (09-17-2018), Betsy859 (10-18-2018)
Old 09-16-2018, 07:46 PM #9
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default

Quote:
Originally Posted by zanpar321 View Post
If the present trials show continued safety and success will this drug get fast track status as a breakthrough therapy? Indications so far sure suggest that it qualifies!

Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review
Although maybe it’s technically possible it would be highly unlikely for this to happen. Fast track is used for new molecules that are ground breaking and greatly needed for a particular disease. There is no need for that in this case as this is already an approved drug. It’s available for any doctor to legally prescribe, if they believe it would be an effective treatment. If data comes out to compel the fda, which hasn’t happened yet, it would just make it easier for doctors to prescribe. So, I don’t think the fda would feel compelling pressure to fast track.
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
anagirl (09-17-2018), Betsy859 (10-18-2018), jeffreyn (09-16-2018), zanpar321 (09-17-2018)
Old 09-16-2018, 08:08 PM #10
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Tupelo3 Tupelo3 is offline
Member
 
Join Date: Mar 2013
Location: New Jersey
Posts: 832
10 yr Member
Default

Quote:
Originally Posted by zanpar321 View Post
Is Radotinib ABL to beat Nilotinib? | The Science of Parkinson's

June 17, 2018 - The competition to stop/reverse Parkinson's is intense!

Our efforts to slow/halt the progression of Parkinson’s are attempting to attack the condition on many different fronts, and (as in the case of the cAbl-inhibitors and GLP-1 agonists – see previous post) we now have multiple weapons potentially available on some of those battle lines.

Ironically in another recent post I commented about the crazy pace of the research at the moment (Click here for that post), and this post is a perfect example of that manic speed. Just days after publishing fascinating results dealing with a novel GLP-1 agonist in models of Parkinson’s, that same research group – led by Prof Han Seok Ko of Johns Hopkins University Medical school – published the research report that was reviewed in this post dealing with a completely different type of drug that exhibits interesting properties in models of Parkinson’s.

A lot of excitement is associated with the efforts to re-purpose the cancer drug Nilotinib for Parkinson’s, and today’s post reinforces the idea that other pharmaceutical companies are also focusing on shifting similar ABL inhibitor drugs to neurodegenerative conditions.

It will be interesting to see how quickly Ilyang Pharmaceutical initiates clinical testing of Radotinib for Parkinson’s.
Yes, there are better versions of both c-abl inhibitors and glp-1 agonists in development. There are three ongoing trials for approved glp-1 agonists with several newer ones still in clinical research for approval. We willing be reviewing funding applications next week at the LinkedIn Clinical Trials annual meeting for a newly approved c-abl inhibitor and glp-1 agonist to possibly begin neurological research.
Tupelo3 is offline   Reply With QuoteReply With Quote
"Thanks for this!" says:
anagirl (09-17-2018), Betsy859 (10-18-2018), eds195 (09-17-2018), jeffreyn (09-16-2018), zanpar321 (09-17-2018)
Reply

Tags
dopamine, modulate, parkinson’s, potential, trial

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Gocovri Improves Dyskinesia in Parkinson’s Patients Over Long Term, Phase 3 Trial eds195 Parkinson's Disease 2 04-28-2018 05:19 AM
MRI-Focused Ultrasound Undergoing Phase 3 Clinical Trial for Parkinson’s Treatment eds195 Parkinson's Disease 3 03-18-2018 10:46 AM
Phase 2 Trial Testing Leukemia Treatment, Nilotinib eds195 Parkinson's Disease 2 03-08-2018 02:10 PM
Voyager’s Gene Therapy to Enter Phase 2/3 Trial Program for Adv Parkinson’s Dise eds195 Parkinson's Disease 0 01-29-2018 05:01 PM
Recruitment has begun for the Georgetown University "PD Nilotinib" phase 2 trial jeffreyn Parkinson's Disease 3 02-26-2017 07:05 PM


All times are GMT -5. The time now is 04:15 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.